Clinical Trial Update: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describing a study of four medicines (Elranatamab plus carfilzomib and dexamethasone or Maplirpacept) in adults with relapsed/re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Elranatamab (elranatamab)
• Maplirpacept (PF-07901801)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING